Abstract
Background and Aim. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is well recognized as a powerful diagnostic tool in the initial staging of patients with multiple myeloma (MM). The aim of this paper is to perform a systematic review about the usefulness of FDG-PET or PET/CT in evaluating the response to treatment in patients with MM. Methods. The scientific literature about the role of FDG-PET or PET/CT in evaluating the response to treatment in patients affected by MM was systematically reviewed. Results. Ten studies about the role of FDG-PET or PET/CT in evaluating treatment response in MM were retrieved and discussed. Conclusions. FDG-PET or PET/CT seems to be helpful in assessing the response to treatment in patients with MM and in the evaluation of possible sites of recurrent or progressive disease.
Highlights
Multiple myeloma (MM) is the second most common haematological malignancy
Qualitative evaluation relies on the visual detection of focal sites of FDG uptake, whereas semiquantitative assessment is usually based on the calculation of standardized uptake value (SUV), which is a measure of glycolytic activity of the neoplastic lesions [3]
fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography (CT) mostly showed more lytic lesions than conventional whole-body X-ray, excepted for skull lesions; magnetic resonance imaging (MRI) seems to be less sensitive than FDG-PET or PET/CT, especially for the detection of extramedullary lesions, but more sensitive when the disease is diffusely spread through the spine [3, 5, 6]
Summary
Multiple myeloma (MM) is the second most common haematological malignancy. It accounts for
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
